1. Evaluating Translational Research:A Process Marker
ModelWilliam Trochim , Ph.D. , Cathleen Kane ,M.P.A., Mark J.
Graham, Ph.D. , andHarold A. Pincus , M.D.
2. What is Translational Research? Translating knowledge gained
from laboratoryscience into clinical practice to improve health
Focus is on the integration of activities frombench to
bedside.
3. The aim of translational research is toproduce
new:TherapeuticsMedical devicesTools for diagnosing diseaseAvenues
for community engagement research
4. The Translation ContinuumSource: National Cancer
InstituteBasicScientificDiscoveryEarlyTranslationLateTranslationDissemination
AdoptionPromisinggeneBasicepidemiologicalfindingPartnershipsInterventiondevelopmentPhase
III trialsRegulatoryapprovalPartnershipsHealth servicesresearch
tosupportdisseminationand adoptionTo communityprovidersTo patients
andpublicAdoption ofadvance byproviders,patients,
andpublicPaymentmechanisms toenable adoption
5. The National Institutes of Health (NIH) havemade it a
central priority, part of theirRoadmap initiative. One of their
primary programs, the Clinical andTranslational Science Awards
(CTSAs) 350 million per year to fund 55 research centers In 2012 -
fund 60 centers at a cost ofapproximately a half billion dollars
per year,making it the largest program at NIH
6. One of the most significant motivations comesfrom a
relatively small number of studies thatshow that it takes a long
time to move basicscientific ideas to practice and health impacts
It takes an estimated average of 17 years foronly 14% of new
scientific discoveries to enterday-to-day clinical practice
7. This time lag is seen as too long, certainly longerthan
necessary Must be a better way to move research to practicemore
quickly without sacrificing quality orincreasing costs. Proposed
solutions include everything from better management of scientific
research increased process efficiency wholesale rethinking of the
biomedical research-practiceendeavor for the 21st century.
8. Models of TranslationalResearch
9. Westfall et all
10. Dougherty and Conway Feedback loopsBroader setting
overtime
11. Khoury et allResearch that describes, interprets and
predicts the impact of variousinfluences, especially (but not
exclusively) interventions of final endpointsthat matter to
decision makers
12. Translational Research ModelSynthesis
13. Multiple competing models Different and conflicting numbers
anddefinitions of translational research phases Complicate
communication about translationalresearch generally Risk of
confusing interpretations ofevaluations
14. The particular dilemma for translational researchevaluators
translational Tower of Babel Same phase label is used for very
differentoperational stages in the research practicecontinuum,
makes cross-evaluation comparisons and synthesesespecially
problematic.
15. First, and perhaps most important, all of themcharacterize
translational research as atemporal process moving from basic to
clinicalto postclinical research and ultimately to useand public
health impact All of them also incorporate the idea
ofbidirectionality
16. Second, the three alternative models to Sunget al.s T1/T2
model differ in how finely theydivide their T1 and T2 phases.
17. Westfall et al. believe that practice-basedresearch needs
to be highlighted Dougherty and Conway want to be sure to note
thedistinction between efficacy and effectivenessstudies in
clinical contexts Khoury et al. want to preserve the
efficacyeffectiveness distinction and make one betweenoutcomes
research and other types ofpostguidelines work
18. Leading to ever more complex models, andcontradictory
classification schemes
19. Third, all of the models make a basicdistinction between
research that takes placebefore and after the development
ofsynthesized clinical trial knowledge at thepoint of demarcation
between T1 and T2. This distinction between pre- and
postclinicalsynthesis may represent a critical jump fromindividual
clinical studies (before) to moresynthesized general knowledge that
cutsacross studies (after).
20. A General Framework forTranslational Research and
ItsEvaluation
21. Process marker model, characterized by the twocomponents
that constitute its name.
22. First, it views translational research as acontinuous
process that moves from basicresearch through clinical,
postclinical, andpractice-based research and ultimately tohealth
policies, outcomes, and impacts. Process may be bidirectional,
variable, andcomplex
23. Second, it assumes that there are many differentpotential
markers along this process.
24. The focus in this model identifying a set of observable
points in the process that can be operationally defined and
measured to enable evaluation of the duration of segments ofthe
research-practice continuum.
25. Model assumes that one would define a numberof operational
markers along a presumedprocess continuum. Assuming that all of the
markers use a commonmeasurement scale (e.g., dates), it is
thenrelatively easy to operationally define thedifference between
any two markers as theduration of time between their dates.
26. What is the correct operational marker touse? A simple
answer is that there is not a singlecorrect markerdifferent markers
simplyrepresent different reference points in anassumed continuous
process. That said, some markers may be better thanothers for
different purposes and in differentcontexts
27. Another consideration is that some markersare likely to be
encountered by more protocolsthan others. Since protocols can take
different pathways inthe process of translation, one would
generallywant to select markers that are more likely tobe commonly
passed
28. Another consideration is that there are likelyto be
subprocesses that get repeatedthroughout the overall translational
process. For instance, the subprocess of conducting,replicating,
and using a research study followsthe same basic steps regardless
of whether itis a basic, clinical, or postclinical study Look at
the durations between two steps inthis subprocess
29. Characteristics that commend the process markerframework
over multiphase models: Avoids theoretical presumptions and
undefinedabstractions Emphasizes observable measurable
phenomena,allowing anyone to readily see how any marker isdefined
Avoids the debates about how many phases thereare in translational
research, while enablingevaluators to use phased-based approaches
as longas they operationally define what they mean.
30. Encourages replicability Robust and forgiving ie, missing
data andvariable protocol pathways can beaccommodated Encourage
development of new hypothesesthat involve more precise
operationaldefinitions
31. Avoids debates about the scope oftranslational research ie,
the scope oftranslation being examined in any given processmarker
evaluation is simply the process that isencompassed between the
first and lastmarker measured Applied prospectively or
retrospectively
32. The process marker model is firmly rooted in aprocess
modeling research tradition in biomedicalresearch as well as in
other fields such as qualitycontrol and assurance
33. Important features of this approach Evaluate translational
research at any level ofscale Provides a foundation for the
evaluation ofinterventions designed to improve
translationalresearch and the integration of these findingsinto a
field of translational studies
34. The process marker model provides a commonframework that
can link these many and variedstudies together Assess whether such
interventions contribute toreducing time to translation
35. Important challenges May lead to complex and difficult
tocommunicate models of translational research Relies upon
descriptive statisticssuch asmedian durationsas the heart of the
results
36. Increased application of an operational processmarker
approach to the study of translationalresearch is likely to lead to
considerableevolution and adaption over time. The field will be
able to determine empiricallythe degree to which various markers
arefeasible to measure and yield results that havevalue for our
understanding of translation
37. Conclusion Translational research is critical to the
evolutionof biomedical research and practice in the 21stcentury The
key problems that led to its emergencetherelatively long time from
discovery to use andimpactand the relatively low proportion
ofdiscoveries that survive that journeyremain achallenge
Significant investments in translational researchare already being
made
38. Evaluation will be essential for managingtranslational
research effectively, learningwhat works and what does not, and
beingaccountable for these investments The current state of
conceptual models anddefinitions of translational research
posessignificant challenges to our ability to evaluate
39. There is considerable disagreement aboutmany of the key
characteristics associatedwith translational research Translational
research involves movement alongthe research-practice continuum,
ultimately tohealth impacts.
40. It is clear from that the unit of translationthe thing that
is being translatedcanchange dramatically across the span of
theresearch-practice continuum While there is also wide acceptance
that theend point of translational research isultimately in health
outcomes and impacts,many of the translational research
activitieswill not directly touch on health impacts
41. Stay with the data in the form of operationallydefinable
markers (measures) on the pathwaysfrom basic research to health
impacts. If multiphase classification systems are used
inevaluations, indicate clearly whose definition ofphases are
employed and how the different phasesare being operationalized. In
the meantime broader translational researchcommunity to collect
feedback regarding variousevaluation measurement challenges